S. 2387 · 116th Congress
We PAID Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
Van HollenSponsor1 cosponsor · 1 R
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
We Protect American Investment in Drugs Act or the We PAID Act
What it does: CRS summary · Introduced in Senate · Jul 31, 2019
We Protect American Investment in Drugs Act or the We PAID Act
This bill limits the price of certain prescription drugs that rely on patents developed with federal support.
The bill requires the Department of Health and Human Services to contract with the National Academy of Medicine to conduct a study for determining the reasonableness of the price of such prescription drugs. The bill also establishes the Drug Affordability and Access Committee, which must use the study to develop a methodology and then determine whether the price of each applicable drug is reasonable after the drug enters the market.
Further, the bill establishes certain pricing requirements for such prescription drugs. First, the manufacturer must submit to the committee the list and retail prices for the drug as well as specified expenditure information. Second, after a drug is on the market for one year, the manufacture must set the drug’s list price at no more than the committee’s reasonable price determination. Third, subsequent price increases are capped at the annual percentage change in the medical care consumer price index for prescription drugs. The penalties for noncompliance with these requirements include expiration of marketing exclusivity, fines, and prohibitions on entering licensing agreements for the applicable drug.
Additionally, the bill revises the patent application requirements for drugs to include the disclosure of specified federal grants.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: We PAID Act
Also known as: We Protect American Investment in Drugs Act
Latest action (Jul 31, 2019): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Jul 31, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.